June 4, 2011 (Chicago, Illinois) — The aromatase inhibitor exemestane offers a new option for breast cancer prevention in postmenopausal women at high risk for the disease. Data from the Mammary ...
January 18, 2011 — Exemestane used alone for 5 years is similar to exemestane used after 2 to 3 years of tamoxifen in the prevention of relapse in postmenopausal women with hormone-responsive early ...
Exemestane modestly enhanced bone loss from the femoral neck without significant influence on lumbar bone loss. Except for a 6% to 9% drop in plasma high-density lipoprotein cholesterol, no major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results